Alcon launches Systane PRO Preservative-Free in Canada, delivering up to 12 hours of dry eye relief
Dry eye disease (DED) is one of the most common ocular surface disorders, affecting an estimated 6 million people in Canada and 1.6 billion globally.
Alcon
Alcon to acquire STAAR Surgical
STAAR Surgical is a leader in refractive surgery using Implantable Collamer Lenses, offering solutions for moderate to high myopes.
Alcon announces U.S. roll out of TRYPTYR, a new prescription treatment option for millions of dry eye sufferers
TRYPTYR is a first-in-class TRPM8 receptor agonist for the treatment of the signs and symptoms of Dry Eye Disease (DED) that rapidly stimulates natural tear production as early as Day 1.
Alcon to acquire LumiThera
LumiThera’s PBM is the only device that has demonstrated meaningful vision improvement compared to baseline for people living with early to intermediate dry AMD.
Alcon announces FDA approval of TRYPTYR for Dry Eye Disease
In pivotal Phase 3 trials, TRYPTYR demonstrated rapid natural tear production as early as Day 1